Celgene reports positive data from multiple myeloma drug trial

Celgene has announced new phase III trial data showing the benefits its drug Revlimid could offer in the treatment of newly-diagnosed multiple myeloma.

Results from the First study showed that the therapy, when used in combination with dexamethasone, was able to deliver progression-free survival benefits among members of this patient group.

Revlimid therefore met its primary efficacy endpoint in the trial, which is also known as MM-020/IFM 07-01 and is one of the largest randomised international phase III studies ever conducted for newly-diagnosed multiple myeloma.

Currently, the drug is not approved for the treatment of patients with this condition in any country, but Celgene plans to commence discussions with regulatory authorities and submit dossiers for registration in the US, Europe and other markets, with data from the First trial to be used as evidence.

This comes after Celgene recently announced a new multiple myeloma research collaboration with MorphoSys, focusing on the development of a new drug called MOR202.